Compare Entegris Inc (ENTG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Entegris Inc trades at $133.42 (market cap $21.12B), while Vertex Pharmaceuticals Incorporated trades at $485.68 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.7× Entegris Inc's market cap, and Entegris Inc pays a 0.29% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ENTG | VRTX | |
|---|---|---|
Market Cap | $21.12B | $121.09B |
Sector | Technology | Health |
52-Week High | $184.00 | $529.59 |
52-Week Low | $68.80 | $366.54 |
Enterprise Value | $24.44B | $115.83B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $134.15, down 4.61% today, with technical indicators showing bearish momentum as the stock approaches key support at $133. The company maintains solid fundamentals with Q1 2026 earnings beating estimates at $0.86 per share and strong analyst consensus of 65% buy ratings. Recent developments include a $0.10 dividend declaration and new CFO appointment, while semiconductor industry tailwinds from AI-driven demand provide growth catalysts.
ENTG presents a compelling opportunity with 25% upside to the $178.40 consensus price target, supported by improving cash flow trends and semiconductor sector growth. However, elevated valuation multiples (P/E 80.17) and technical bearish signals warrant caution amid recent price volatility and competitive pressures in the semiconductor materials space.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
